European Respiratory Journal - McMaster Experts

publication venue for

ALIENTO and ARNASA: Study designs of two randomised, double-blind, placebo-controlled trials of astegolimab in patients with COPD 2023
Airway autoimmunity in asthma is associated with an aggravated inflammatory response to viral stimulation of the bronchial epithelium 2023
Are physical activity levels different between non-frail and pre-frail patients with COPD? 2023
Assessment of eosinophilic airway inflammation using formalin-fixed, paraffin-embedded sputum plugs 2023
Association of multiple factors with childhood asthma and allergic diseases: a latent class analysis 2023
Associations between sputum cell counts and healthcare use across Ontario patients with asthma or COPD 2023
Asthma outcomes in patients (pts) with severe eosinophilic asthma (SEA), with and without comorbid chronic rhinosinusitis with nasal polyps (NP), treated with benralizumab in the real-world XALOC-1 study 2023
Benralizumab effectiveness in patients with severe asthma regardless of prior biologic use: A real-world Canadian experience 2023
Burden of chronic dry and productive cough on social participation, healthcare resource utilisation and activities of daily living from the Canadian Longitudinal Study on Aging (CLSA) 2023
Charcot-Leyden crystals are associated with airway autoimmune responses in severe asthma 2023
Cut-off of the chester step test to detect functional impairment and mortality risk according to the 6MWT in ILD 2023
Cytokine and chemokine signature of COVID-19 and predictive markers 2023
Demographics and subjective cough outcomes of guideline-based treatment in the McMaster Cough Clinic. 2023
Effectiveness and cost of a comprehensive severe asthma management strategy guided by airway inflammometry 2023
Effectiveness of PersonalIsed CommUnity-based Physical activities for people with chronic obstructive pulmonary disease (PICk UP) 2023
Effects of nintedanib on circulating biomarkers in patients with progressive pulmonary fibrosis: subgroups by fibrotic pattern on HRCT 2023
Effects of pulmonary rehabilitation on cough-related quality of life in people with chronic respiratory disease 2023
Effects of self-management interventions in people with interstitial lung disease - systematic review and meta-analysis 2023
Efficacy and safety of gefapixant for treatment of refractory or unexplained chronic cough: a systematic review and dose-response meta-analysis 2023
Endothelial cellular senescence contributes to the pathogenesis of IPF with pulmonary hypertension 2023
Eosinophil phenotypes in circulation and airways of asthmatics after inhaled allergen challenge. 2023
Functional recovery over 1 year after hospitalization for COVID-19: results from waves 1 and 2 of the pandemic 2023
Identifying the common denominator: Dectin-1 as a promising marker for macrophage modulation in lung cancer and fibrosis 2023
Impact of COPD on lung cancer symptom burden: A population-based study 2023
Late Breaking Abstract - Patients with severe eosinophilic asthma achieved remission over 2 years with benralizumab: Integrated analysis of the >1000-patient, multinational, real-world XALOC-1 study 2023
Living with chronic cough: experiences, burden and management in ILD – a qualitative Study 2023
Multisite implementation of 129Xe-MRI assessment of COPD disease progression: XeCITE early results 2023
Non-T2 cytokines post Benralizumab associate with residual symptoms 2023
Perceptions and beliefs associated with enrolling in pulmonary rehabilitation 2023
Prognostic value of circulating biomarkers in patients with progressive pulmonary fibrosis 2023
Relationship between measures of type II inflammation and patient reported cough severity and quality of life outcomes in patients with chronic cough 2023
Relationship between subjective cough outcomes and activity impairment in patients with chronic cough 2023
Role of virtual multidisciplinary team meetings in the post-COVID era: a global survey to evaluate the ILD diagnostic pathway 2023
Self-selected music listening during pulmonary rehabilitation in people with COPD: a multi-centre, randomised controlled trial. 2023
Surface receptor expression on circulating and airway eosinophils after inhaled allergen challenge 2023
TSLP gene polymorphisms and alarmin protein levels in COVID-19 2023
The clinical frailty scale is associated with progression of fibrotic interstitial lung disease – a multicentre cohort study. 2023
Usability of the OnTRACK platform to promote physical activity in COPD 2023
Win ratio approach to assessing the effect of nintedanib on a hierarchical composite endpoint in patients with progressive pulmonary fibrosis 2023
Work productivity and activity impairment among chronic cough patients after a guideline-based treatment in the McMaster Cough Clinic 2023
Accuracy of a wearable device for assessing sedentary behavior in Chronic Obstructive Pulmonary Disease 2022
Alarmin Expression in the Upper and Lower Airways of Asthmatics with Allergic Rhinitis 2022
Asthma exacerbation rate reduction with benralizumab in an integrated analysis of the real-world XALOC-1 study 2022
Awake Prone Positioning in Acute Hypoxemic Respiratory Failure from COVID-19: A Randomized Clinical Trial 2022
Benralizumab attenuates blood and airway eosinophilia in severe asthmatics with inadequate response to anti-IL-5 neutralizing antibodies 2022
Benralizumab continues to improve quality of life after 6 months of treatment in Canadians with severe eosinophilic asthma 2022
Canadian health care professionals’ experiences diagnosing chronic cough – results from a healthcare survey 2022
Canadian health care professionals’ familiarity with chronic cough, its impact on patients, and guideline recommendations of the diagnosis and treatment of chronic cough 2022
Canadian health care professionals’ perceptions on the management and effectiveness of treatment of chronic cough – results from a healthcare sample survey 2022
Capsaicin evoked cough responses and the effect of sex hormones 2022
Comparison of upper and lower airway expression of SARS-COV-2 receptors in mild allergic asthmatics 2022
Determinants of DLCO and contribution to exercise capacity and symptoms 2022
Eccentric diaphragmatic contractions during mechanical ventilation in critically ill patients 2022
End-users’ perspectives of an eHealth platform to promote physical activity in COPD: a qualitative study 2022
Features and quality of COPD self-management apps in the Android marketplace 2022
Functional recovery of hospitalised patients with covid-19: a prospective cohort study 2022
Higher versus lower dose corticosteroids for moderate to severe COVID-19: a systematic review, dose response and network meta-analysis. 2022
Impact of ActiGraph® cutoffs on time spent in moderate to vigorous physical activities in COPD. 2022
Impact of mental health and personality traits on the incidence of chronic cough in the Canadian Longitudinal Study on Aging (CLSA) 2022
Measurement properties of walk tests in interstitial lung diseases 2022
Nasal polyposis in severe asthma is associated with airway autoimmunity towards eosinophils and macrophages 2022
Phosphoinositide 3-kinase and airway infections in severe asthmatics 2022
Phosphoinositide-3 kinase antagonism does not reverse steroid insensitivity in severe asthma 2022
Rapid Access Rehabilitation after exacerbations of COPD – an international Delphi study 2022
Reduced ACE2 and TMPRSS2 immunopositive bronchial cells in asthmatics after inhaled allergen challenge 2022
Reduction in work and activity impairment within 6 months of benralizumab initiation in Canadians with severe eosinophilic asthma 2022
Respiratory system resistance and reactance following recovery from non-critical COVID-19 2022
Sustained improvement of asthma control over 6 months of benralizumab treatment in Canadians with severe asthma 2022
The Effect of Inhaled Salbutamol on Mannitol Evoked Cough Responses: A Double-Blind Randomized Placebo Controlled 2-way Cross-Over Study 2022
Validation of cough monitoring by Albus Home RD, a contactless bedside device for nocturnal monitoring 2022
An electronic patient decision aid comparing as-needed budesonide-formoterol combination to regular use of inhaled corticosteroid (ICS) in mild asthma: a rapid-cycle design study 2021
Characteristics of a real world cohort of Canadians treated with benralizumab 2021
Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma 2021
Motivation and physical activity in COPD: an exploratory study 2021
Prevalence, incidence, and characteristics of chronic cough among adults from the canadian longitudinal study on ageing (CLSA) 2021
Prompting sedentary behaviour change in COPD: Acceptability and feasibility of wearable device 2021
Quality and methodology of clinical practice guidelines on antiviral pharmacotherapy for COVID-19 during the early phase of the pandemic 2021
Rapid Access Rehabilitation after exacerbations of COPD – A qualitative study 2021
Relationship between fatigue, physical activity and health-related factors in COPD 2021
The impact of Beta Blockade on cardio-respiratory system and symptoms during exercise 2021
Unsupervised physical activity interventions for people with COPD: a systematic review 2021
Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma 2020
Assessing the caregiving experience in COPD: content validity of the Zarit Burden Interview and Caregiver Reaction Assessment 2020
CD6-ALCAM Pathway is Elevated in Patients with Severe Asthma 2020
Characterisation of the neutrophilic asthma phenotype over time 2020
Characteristics of patients with COPD using mobile apps in daily life 2020
Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps 2020
Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2 2020
Home-based fall prevention for older adults with COPD: a feasibility study 2020
How is ultrasound imaging being used to assess respiratory musculature? A systematic review 2020
Late Breaking Abstract - Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients 2020
Outcomes in exercise-based interventions in interstitial lung diseases 2020
Real-world treatment patterns of mepolizumab therapy in Canada 2020
A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma 2019
An assessment of the use of palivizumab over 12 years from a Canadian Registry (CARESS) 2019
Exacerbation risk after night-time waking due to asthma in SYGMA 1 2019
Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma 2019
Psychometric properties of measures of field-based exercise test capacity in individuals with asthma: a systematic review 2019
Relationship between distress and physical activity in informal carers of patients with COPD 2019
Relationship between exposure to household air pollution and asthma in children: a systematic review and meta-analysis 2019
The prevalence of bronchitis and associations with spirometry in patients with interstitial lungdisease in a Canadian tertiary care centre 2019
Understanding the relationship between breastfeeding and childhood asthma: A systematic review and meta-analysis 2019
Assessing caregiving experience in COPD: content validity of the Zarit Burden Interview 2018
Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance 2018
Diffuse panbronchiolitis is not restricted to east asia - A mini literature review 2018
Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study 2018
Increased sputum B cells in severe eosinophilic asthma: a local auto-inflammatory process 2018
Interval versus continuous cycling in advanced interstitial lung disease 2018
Investigating the safety of capsaicin cough challenge in severe asthma 2018
Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma 2018
Skeletal limb muscle oxygenation and regional blood volume during incremental loading in interstitial lung disease 2018
The DIAPHRAGM study: Diagnostic and prognostic biomarkers in the rational assessment of Mesothelioma 2018
A novel device for the measurement of carbon dioxide during tidal breathing in COPD 2017
A study to assess airway remodelling and the utility of low dose CT scoring to evaluate the asthmatic airway 2017
A study to define microbiome subtypes in the adult asthmatic airway 2017
A study to define the microbiome of the asthmatic airway 2017
Benralizumab attenuates airway eosinophilopoietic processes in prednisone-dependent asthma 2017
Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD 2017
Chronic cough: Are we integrating non-pharmacological therapies into treatment plans? 2017
Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis 2017
Lung clearance index is increased in high-risk preschool wheezers and is associated with asthma control 2017
Normative values for the Unsupported Upper Limb Exercise (UULEX) test and 6-min Pegboard and Ring test (6PBRT) in healthy Canadian adults 2017
The effect of an acute exacerbation of COPD (AECOPD) on balance after pulmonary rehabilitation (PR): a prospective study 2017
The views of health care providers’ (HCPs) and patients with Chronic Obstructive Pulmonary Disease (COPD) on pain in pulmonary rehabilitation (PR): A qualitative study 2017
Weight-adjusted Intravenous Reslizumab Attenuates Airway Eosinophilia in Severe Asthmatics compared to 100 mg Subcutaneous Mepolizumab 2017
Cardiovascular Safety Of Nintedanib In Subgroups By Cardiovascular Risk At Baseline In The Tomorrow And Inpulsis Trials 2017
An exploration of pain experiences and their meaning in people with chronic obstructive pulmonary disease (COPD) 2016
Cardiorespiratory physiotherapy as a career choice in Portugal 2016
Inhaled diesel exhaust alters allergen-induced bronchial secretome in humans 2016
Investigating the interaction between bronchoconstriction and cough in asthma 2016
LSC Abstract – Systems approach to predict asthmatic response to allergen inhalation challenge 2016
Mepolizumab in COPD with eosinophilic bronchitis: A randomized clinical trial 2016
Postural abnormalities in people with chronic obstructive pulmonary disease (COPD) 2016
Specific parental atopy, sex of child and timing of introduction of 'allergenic' foods 2016
Tracking pulmonary exacerbations in preschool children using the lung clearance index 2016
Walk2Bactive: Patients' perspectives of a physical activity-focused intervention beyond pulmonary rehabilitation in COPD 2016
A novel approach to evaluate trunk geometric-motion during rest and with postural changes 2015
Accuracy of piezoelectric pedometer step counts in different wearing locations 2015
COPD and risk of cardiovascular disease: A prospective study of 0.5M Chinese adults 2015
Does the lung clearance index track with disease progression in early childhood? 2015
Early life gut microbial alterations in children diagnosed with asthma by three years of age 2015
Feasibility of performing pulmonary function testing in cohort studies 2015
LATE-BREAKING ABSTRACT: A novel role for CCR3 in promoting airways hyperreactivity; Role for CCR3-muscarinic M3 receptor heterodimers 2015
Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations 2015
QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study 2015
Relationship of cold frequency and virus detection to exacerbations in COPD patients 2015
Respiratory related hospitalizations in premature infants prophylaxed with palivizumab In the Canadian registry of palivizumab (CARESS) 2015
Risk of cardiovascular events following COPD hospitalisation: Findings from the China Kadoorie Biobank cohort study 2015
Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study 2015
Self-report vs. pedometer steps in COPD: Are they similar? 2015
The dynamic change of IL-25 and its receptor expression during allergen challenge in asthmatic subjects 2015
Tri-level ventilation versus CPAP treatment in treatment of complex sleep apnoea syndrome 2015
Working with families: Lessons from a Canadian registry of palivizumab use 2015
Arm activity in daily life in chronic obstructive pulmonary disease (COPD) 2014
As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study 2014
As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study 2014
As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study 2014
Blockade of TSLP pathway alters asthma biomarkers 2014
Blockade of TSLP pathway alters asthma biomarkers 2014
Cluster analysis of objectively measured physical activity in 1001 COPD patients 2014
Does family support affect physical activity of patients with COPD? An exploratory study 2014
Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis 2014
Exposure to household air pollution and respiratory symptoms in Nepal: A cross-sectional study 2014
Late-breaking abstract: Efficacy and safety of multiple doses of QGEo31 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen induced early asthmatic response 2014
Mast cells infiltrate the alveolar parenchyma in young children with respiratory viral infections 2014
Respiratory syncytial virus (RSV) hospitalization in infants with congenital airway anomalies (CAA) in the canadian registry of palivizumab (CARESS) after prophylaxis (2005-2012) 2014
Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma 2013
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma 2013
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma 2013
Efficacy of budesonide/formoterol maintenance and reliever therapy in mild asthma 2013
Excess inhaled corticosteroid adherence may be a marker of uncontrolled asthma 2013
Family integration in pulmonary rehabilitation programmes: A pilot study 2013
Geographical variation of prevalence, and under-diagnosis of COPD in urban and rural communities of China: Finding from China Kadoorie Biobank of 0.5M people 2013
Interdependence of HIF1 alpha/TGF beta 1 activity in induction of pulmonary fibrosis 2013
Job exposure matrix development for SOC 2000 occupational codes 2013
Magnitude of the late allergen response in seasonal vs perennial allergen bronchoprovocation 2013
Mechanisms regulating enhanced alpha v beta 6 expression in pulmonary fibrosis 2013
Mechanisms regulating enhanced alpha v beta 6 expression in pulmonary fibrosis 2013
Neuromechanical uncoupling of the respiratory system during exercise in patients with mild COPD 2013
Objective moderate-to-vigorous physical activity in 1064 patients with COPD after stratification for gender, FEV1 and BMI 2013
Peripheral blood Th17 / Treg ratio increases in late asthmatic response 2013
Prevalence and determinants of COPD in 320,000 never smokers in China: Results from the China Kadoorie Biobank study 2013
RSV hospitalization in cystic fibrosis in the Canadian registry of palivizumab (CARESS) following prophylaxis (2005-2012) 2013
RSV hospitalization in infants with neuromuscular disease in the Canadian registry of palivizumab after prophylaxis (2005-2012) 2013
Real-life asthma impairment: SABA use depends on smoking phenotype 2013
Systematic review of job exposure matrix used in population COPD studies 2013
The NLRP3 inflammasome is not activated in airway smooth muscle upon TLR2 ligation 2013
The burden of asthma in Canadian children and adolescents of South Asian descent 2013
Abnormalities in lung clearance index in CF infants diagnosed by newborn screening 2012
Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis 2012
Assessing the standard and accuracy of chest x-ray reporting by medical physicians in an acute medical take 2012
Factors associated with compliance with palivizumab treatment in the Canadian rSV evaluation study for synagis (CARESS) registry (32005-2011) 2012
RSV hospitalization in Down syndrome in the Canadian Registry of Synagis (CARESS) following prophylaxis (2006-2011) 2012
Risk factors that determine time to first RSV hospitalization in CARESS: The Canadian registry of palivizumab (2005-2011) 2012
Validation of multiple breath washout technology in healthy children and children with CF 2012
Drug-induced infiltrative lung disease. 2001
Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.. 2400691. 2024
The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough.. 2401565. 2024
Worsening dyspnoea as a predictor of progression of pulmonary fibrosis.. 64:2302211. 2024
Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial. 64:2400512-2400512. 2024
European Respiratory Society Statement on preschool wheezing disorders: updated definitions, knowledge gaps, and proposed future research directions. 64:2400624-2400624. 2024
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. 64:2301521-2301521. 2024
Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. 63:2400061-2400061. 2024
Core outcome measurement set for research and clinical practice in post-COVID-19 condition (long COVID) in children and young people: an international Delphi consensus study “PC-COS Children”. 63:2301761-2301761. 2024
Reshaping the fabric of health: a call for improving the respiratory health of textile workers in low- and middle-income countries. 63:2301803-2301803. 2024
Leukocyte telomere length: the dawn of a new era of personalised medicine in fibrotic interstitial lung diseases?. 62:2301852-2301852. 2023
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort. 62:2300925-2300925. 2023
Endothelial cells in pulmonary fibrosis: more than a bystander. 61:2300407-2300407. 2023
A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity. 61:2300653-2300653. 2023
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. 61:2202163-2202163. 2023
Another piece in the pirfenidone puzzle. 61:2300240-2300240. 2023
Design considerations and implications of findings on progressive pulmonary fibrosis from the prospective Canadian Registry for Pulmonary Fibrosis. 61:2300208-2300208. 2023
Idiopathic pulmonary fibrosis: state of the art for 2023. 61:2200957-2200957. 2023
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. 61:2201193-2201193. 2023
Progressive pulmonary fibrosis: an expert group consensus statement. 61:2103187-2103187. 2023
European Respiratory Society guideline on various aspects of quality in lung cancer care. 61:2103201-2103201. 2023
Nintedanib in chILD: a small step, yes… but at least a step forward in a marathon!. 61:2201797-2201797. 2023
3D (bio)printing of lungs: past, present, and future. 61:2200417-2200417. 2023
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. 61:2200970-2200970. 2023
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis. 61:2202261-2202261. 2023
Airway autoantibodies are determinants of asthma severity. 60:2200442-2200442. 2022
Lung cancer in pulmonary fibrosis: no room for nihilism!. 60:2201946-2201946. 2022
Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma. 60:2102446-2102446. 2022
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. 60:2102571-2102571. 2022
European Respiratory Society guidelines for the diagnosis of asthma in adults. 60:2101585-2101585. 2022
Moving the dial on identifying endotypes of asthma from early life. 60:2201031-2201031. 2022
Allergen provocation tests in respiratory research: building on 50 years of experience. 60:2102782-2102782. 2022
Cigarette smoke augments CSF3 expression in neutrophils to compromise alveolar–capillary barrier function during influenza infection. 60:2102049-2102049. 2022
Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. 60:2102951-2102951. 2022
Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?. 60:2102103-2102103. 2022
“International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.” Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, et al. Eur Respir J 2014; 43: 343–373.. 59:1362020-1362020. 2022
Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. 59:2102899-2102899. 2022
Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity. 59:2102210-2102210. 2022
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. 59:2101574-2101574. 2022
Prognostic factors for development of acute respiratory distress syndrome following traumatic injury: a systematic review and meta-analysis. 59:2100857-2100857. 2022
Helmet noninvasive ventilation compared to facemask noninvasive ventilation and high-flow nasal cannula in acute respiratory failure: a systematic review and meta-analysis. 59:2101269-2101269. 2022
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. 59:2004538-2004538. 2022
Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. 59:2101399-2101399. 2022
Tuberculosis and COVID-19 co-infection: description of the global cohort. 59:2102538-2102538. 2022
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. 59:2101471-2101471. 2022
Is tezepelumab more than just an anti-eosinophil drug?. 59:2101700-2101700. 2022
R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life. 59:2100917-2100917. 2022
The evolution of the European Respiratory Journal: adapting in an era of change. 59:2200037-2200037. 2022
Occupational inhalant exposures and longitudinal lung function decline. 58:2004341-2004341. 2021
Association between the renin–angiotensin system and chronic lung allograft dysfunction. 58:2002975-2002975. 2021
Steroid use in elderly critically ill COVID-19 patients. 58:2100979-2100979. 2021
Exercise-induced bronchoconstriction and bronchodilation: investigating the effects of age, sex, airflow limitation and FEV₁. 58:2004026-2004026. 2021
Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis. 58:2100172-2100172. 2021
Repeat bronchoalveolar lavage in idiopathic pulmonary fibrosis: proceed with caution?. 57:2100691-2100691. 2021
Guideline-directed management of COVID-19: Do's and Don'ts. 57:2100753-2100753. 2021
The management of mild asthma. 57:2003051-2003051. 2021
Mononuclear phagocytic system and fibrosis: back to the future?. 57:2004466-2004466. 2021
Reply to: Noxious cold stimulation: pro–con perspectives on the hypothermic effect on experimentally evoked cough. 57:2100245-2100245. 2021
Allergen inhalation generates pro-inflammatory oxidised phosphatidylcholine associated with airway dysfunction. 57:2000839-2000839. 2021
Current smoking status is associated with reduced sputum immunoglobulin M and G expression in COPD. 57:1902338-1902338. 2021
The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. 57:2100079-2100079. 2021
The evolution of the European Respiratory Journal: weathering the publishing pandemic. 57:2100084-2100084. 2021
A golden age of asthma research. 56:2003820-2003820. 2020
The effect of pain conditioning on experimentally evoked cough: evidence of impaired endogenous inhibitory control mechanisms in refractory chronic cough. 56:2001387-2001387. 2020
Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow. 56:2003147-2003147. 2020
“ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.” Alyn H. Morice, Eva Millqvist, Kristina Bieksiene, Surinder S. Birring, Peter Dicpinigaitis, Christian Domingo Ribas, Michele Hilton Boon, Ahmad Kantar, Kefang Lai, Lorcan McGarvey, David Rigau, Imran Satia, Jacky Smith, Woo-Jung Song, Thomy Tonia, Jan W.K. van den Berg, Mirjam J.G. van Manen and Angela Zacharasiewicz. Eur Respir J 2020; 55: 1901136.. 56:1951136-1951136. 2020
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. 56:2000117-2000117. 2020
Cigarette smoke-initiated autoimmunity facilitates sensitisation to elastin-induced COPD-like pathologies in mice. 56:2000404-2000404. 2020
Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. 56:2001123-2001123. 2020
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. 56:2000535-2000535. 2020
TRIM33 prevents pulmonary fibrosis by impairing TGF-β1 signalling. 55:1901346-1901346. 2020
The importance of interventional timing in the bleomycin model of pulmonary fibrosis. 55:1901105-1901105. 2020
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. 55:1901760-1901760. 2020
EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke. 55:1901104-1901104. 2020
Making the case for causality: what role do lung microbiota play in idiopathic pulmonary fibrosis?. 55:2000318-2000318. 2020
Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a Star Wars saga?. 55:2000590-2000590. 2020
WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence. 55:1902325-1902325. 2020
Clinical implications of incidental venous thromboembolism in cancer patients. 55:1901697-1901697. 2020
ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. 55:1901136-1901136. 2020
European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia. 55:1900788-1900788. 2020
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. 55:1900588-1900588. 2020
The evolution of the European Respiratory Journal: ready for the new decade!. 55:1902503-1902503. 2020
From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity. 54:1901023-1901023. 2019
The impact of marijuana smoking on lung function. 54:1902065-1902065. 2019
European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. 54:1901003-1901003. 2019
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. 54:1900161-1900161. 2019
The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group. 54:1901511-1901511. 2019
The Global Initiative for Asthma (GINA): 25 years later. 54:1900598-1900598. 2019
An atypical pulmonary fibrosis is associated with co-inheritance of mutations in the calcium binding protein genes S100A3 and S100A13. 54:1802041-1802041. 2019
Asthma progression and mortality: the role of inhaled corticosteroids. 54:1900491-1900491. 2019
Eosinophil-derived IL-13 promotes emphysema. 53:1801291-1801291. 2019
The Electronic Asthma Management System (eAMS) improves primary care asthma management. 53:1802241-1802241. 2019
Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. 53:1801655-1801655. 2019
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. 53:1800663-1800663. 2019
Pulmonary fibrosis: “idiopathic” is not “cryptogenic”. 53:1900400-1900400. 2019
Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?. 53:1801939-1801939. 2019
Predictors of 1-year compliance with adaptive servoventilation in patients with heart failure and sleep disordered breathing: preliminary data from the ADVENT-HF trial. 53:1801626-1801626. 2019
The interleukin-13 paradox in asthma: effective biology, ineffective biologicals. 53:1802250-1802250. 2019
The evolution of theEuropean Respiratory Journal: volume 2. 53:1802459-1802459. 2019
ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. 52:1801033-1801033. 2018
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension. 52:1701857-1701857. 2018
Radiological diagnosis of interstitial lung disease: is it all about pattern recognition?. 52:1801321-1801321. 2018
Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. 52:1702593-1702593. 2018
A systematic review on how patients value chronic obstructive pulmonary disease outcomes. 52:1800222-1800222. 2018
“International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.” Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, Andrew Bush, Mario Castro, Peter J. Sterk, Ian M. Adcock, Eric D. Bateman, Elisabeth H. Bel, Eugene R. Bleecker, Louis-Philippe Boulet, Christopher Brightling, Pascal Chanez, Sven-Erik Dahlen, Ratko Djukanovic, Urs Frey, Mina Gaga, Peter Gibson, Qutayba Hamid, Nizar N. Jajour, Thais Mauad, Ronald L. Sorkness and W. Gerald Teague. Eur Respir J 2014; 43: 343–373.. 52:1352020-1352020. 2018
What is the minimal clinically important difference for helium-3 magnetic resonance imaging ventilation defects?. 51:1800324-1800324. 2018
Low-dose computed tomography for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study. 51:1702375-1702375. 2018
Optimising experimental research in respiratory diseases: an ERS statement. 51:1702133-1702133. 2018
What's in a name? That which we call IPF, by any other name would act the same. 51:1800692-1800692. 2018
Associations between blood eosinophils and decline in lung function among adults with and without asthma. 51:1702536-1702536. 2018
Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis. 51:1700386-1700386. 2018
“Global strategy for asthma management and prevention: GINA executive summary.” E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, J.M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S.E. Pedersen, E. Pizzichini, S.D. Sullivan, S.E. Wenzel and H.J. Zar.Eur Respir J2008; 31: 143–178.. 51:0751387-0751387. 2018
The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?. 51:1702420-1702420. 2018
Turning thirty: evolution but not revolution at the ERJ. 51:1702594-1702594. 2018
A standardised method for interpreting the association between mutations and phenotypic drug resistance inMycobacterium tuberculosis. 50:1701354-1701354. 2017
Association of wheeze with lung function decline in children with sickle cell disease. 50:1602433-1602433. 2017
Sex-specific impact of asthma during pregnancy on infant gut microbiota. 50:1700280-1700280. 2017
The paradoxes of asthma management: time for a new approach?. 50:1701103-1701103. 2017
Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study. 50:1700936-1700936. 2017
Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. 50:1602426-1602426. 2017
Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. 50:1700216-1700216. 2017
Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage. 49:1700811-1700811. 2017
Breastfeeding, maternal asthma and wheezing in the first year of life: a longitudinal birth cohort study. 49:1602019-1602019. 2017
ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. 49:1601526-1601526. 2017
A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. 49:1602486-1602486. 2017
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. 49:1602308-1602308. 2017
Heat shock protein: a hot topic in idiopathic pulmonary fibrosis. 49:1602152-1602152. 2017
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. 48:1369-1376. 2016
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. 48:1524-1526. 2016
Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. 48:1150-1159. 2016
Pulmonary function tests (PFT) and sleep disordered breathing (SDB) in morbidly obese children and adults:. 48:PA4348-PA4348. 2016
The relationship between body fat and respiratory function in young adults. 48:734-747. 2016
“Plasma pro-surfactant protein B and lung function decline in smokers.” Janice M. Leung, John Mayo, Wan Tan, C. Martin Tammemagi, Geoffrey Liu, Stuart Peacock, Frances A. Shepherd, John Goffin, Glenwood Goss, Garth Nicholas, Alain Tremblay, Michael Johnston, Simon Martel, Francis Laberge, Rick Bhatia, Heidi Roberts, Paul Burrowes, Daria Manos, Lori Stewart, Jean M. Seely, Michel Gingras, Sergio Pasian, Ming-Sound Tsao, Stephen Lam and Don D. Sin, for the Pan-Canadian Early Lung Cancer Study Group.Eur Respir J2015; 45: 1037–1045.. 48:962.2-962. 2016
Is ventilation heterogeneity related to asthma control?. 48:370-379. 2016
Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. 48:187-195. 2016
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. 47:1776-1784. 2016
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. 47:1028-1033. 2016
Management of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countries. 46:1563-1576. 2015
Disruption of pulmonary lipid homeostasis drives cigarette smoke-induced lung inflammation in mice. 46:1451-1460. 2015
Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. 46:1055-1064. 2015
A summary of the new GINA strategy: a roadmap to asthma control. 46:622-639. 2015
Allergen-induced airway responses. 46:819-831. 2015
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. 46:243-249. 2015
Airway diseases and inflammatory bowel diseases: is it something in the air (pollution)?. 46:287-288. 2015
Effects of quitting cannabis on respiratory symptoms. 46:80-87. 2015
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. 45:1434-1445. 2015
Plasma pro-surfactant protein B and lung function decline in smokers. 45:1037-1045. 2015
Smoking, asthma, chronic airflow obstruction and COPD. 45:586-588. 2015
Defining airflow obstruction. 45:563-564. 2015
Impacts of peroxisome proliferator-activated receptor-γ activation on cigarette smoke-induced exacerbated response to bacteria. 45:191-200. 2015
An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. 44:1479-1503. 2014
Mechanisms of exercise intolerance in Global Initiative for Chronic Obstructive Lung Disease grade 1 COPD. 44:1177-1187. 2014
Integrated care pathways for airway diseases (AIRWAYS-ICPs). 44:304-323. 2014
Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. 44:267-267. 2014
Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. 44:267-268. 2014
Prevalence and correlates of airflow obstruction in 317 000 never-smokers in China. 44:66-77. 2014
Differences in content and organisational aspects of pulmonary rehabilitation programmes. 43:1326-1337. 2014
"International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma." Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, Andrew Bush, Mario Castro, Peter J. Sterk, Ian M. Adcock, Eric D. Bateman, Elisabeth H. Bel, Eugene R. Bleecker, Louis-Philippe Boulet, Christopher Brightling, Pascal Chanez, Sven-Erik Dahlen, Ratko Djukanovic, Urs Frey, Mina Gaga, Peter Gibson, Qutayba Hamid, Nizar N. Jajour, Thais Mauad, Ronald L. Sorkness and W. Gerald Teague. Eur Respir J 2014; 43: 343-373.. 43:1216-1216. 2014
Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. 43:817-823. 2014
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. 43:773-782. 2014
Asymmetric dimethylarginine and asthma. 43:647-648. 2014
Disconnect between sputum neutrophils and other measures of airway inflammation in asthma. 43:627-629. 2014
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. 43:343-373. 2014
Safety of formoterol in asthma clinical trials: an update. 43:103-114. 2014
“Biomarker-guided clinical decisions: for patients, health economists or neither?” Jens-Ulrik Jensen.Eur Respir J2013; 42: 895–897.. 42:1432.2-1432. 2013
Sample sizes for clinical trials using sputum eosinophils as a primary outcome. 42:1003-1011. 2013
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. 42:230-238. 2013
Age and height dependence of lung clearance index and functional residual capacity. 41:1371-1377. 2013
Consensus statement for inert gas washout measurement using multiple- and single- breath tests. 41:507-522. 2013
PPAR ligands decrease human airway smooth muscle cell migration and extracellular matrix synthesis. 41:425-432. 2013
Prof. Andrzej Szczeklik, 1938–2012: aspirin-induced asthma and much more. 39:1286-1286. 2012
“Effect of different asthma treatments on risk of cold-related exacerbations.” H.K. Reddel, C. Jenkins, S. Quirce, M.R. Sears, E.D. Bateman, P.M. O'Byrne, M. Humbert, R. Buhl, T. Harrison, G.G. Brusselle, A. Thorén, U. Sjöbring, S. Peterson, O. Östlund and G.S. Eriksson.Eur Respir J2011; 38: 584–593.: Figure 4. 39:1280-1280. 2012
Chest radiotherapy to achieve lung volume reduction. 39:792-792. 2012
Interleukin-18 and interleukin-18 receptor- expression in allergic asthma. 38:981-983. 2011
Effect of different asthma treatments on risk of cold-related exacerbations. 38:584-593. 2011
Mechanisms of dyspnoea relief following radiation treatment in a patient with severe COPD. 38:728-730. 2011
Modulating progenitor accumulation attenuates lung angiogenesis in a mouse model of asthma. 38:679-687. 2011
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. 38:516-528. 2011
A mouse GM-CSF receptor antibody attenuates neutrophilia in mice exposed to cigarette smoke. 38:285-294. 2011
From the authors: The Asthma Control Questionnaire for children: still more questions than answers. 37:1534-1535. 2011
In memoriam Prof. Hisamichi Aizawa, 1950-2011. 37:977-977. 2011
The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. 37:806-812. 2011
The promise of electronic data capture in respiratory medicine. 37:228-230. 2011
Asthma Control Questionnaire in children: validation, measurement properties, interpretation. 36:1410-1416. 2010
Mechanisms of clearance of nontypeable Haemophilus influenzae from cigarette smoke-exposed mouse lungs. 36:1131-1142. 2010
Overexpression of transforming growth factor- 1 in fetal monkey lung results in prenatal pulmonary fibrosis. 36:907-914. 2010
Measuring asthma control: a comparison of three classification systems. 36:269-276. 2010
Bleomycin induces pleural and subpleural fibrosis in the presence of carbon particles. 35:176-185. 2010
Effects of cannabis on lung function: a population-based cohort study. 35:42-47. 2010
Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study. 35:48-53. 2010
Diffuse idiopathic pulmonary neuroendocrine hyperplasia, chronic eosinophilic pneumonia, and asthma. 34:1489-1492. 2009
Validated questionnaires should not be modified. 34:1015-1017. 2009
How to increase the value of randomised trials in COPD research. 34:552-558. 2009
Evaluation of allergic lung inflammation by computed tomography in a rat model in vivo. 33:1437-1447. 2009
Single-dose desloratadine and montelukast and allergen-induced late airway responses. 33:1302-1308. 2009
Asthma therapy: how far have we come, why did we fail and where should we go next?. 33:11-20. 2009
Long-acting -agonists: a review of formoterol safety data from asthma clinical trials. 33:21-32. 2009
Properties of a store-operated nonselective cation channel in airway smooth muscle. 32:1529-1538. 2008
The Brussels Declaration: the need for change in asthma management. 32:1433-1442. 2008
Budesonide prevents but does not reverse sustained airway hyperresponsiveness in mice. 32:970-978. 2008
The effect of inhaled lidocaine-hydrofluoroalkane 134a in prednisone-dependent eosinophilic bronchitis. 32:1119-1122. 2008
A new perspective on concepts of asthma severity and control. 32:545-554. 2008
Interpretation of treatment changes in 6-minute walk distance in patients with COPD. 32:637-643. 2008
Ryanodine receptors decant internal Ca2+ store in human and bovine airway smooth muscle. 32:275-284. 2008
TGF- receptor II in epithelia versus mesenchyme plays distinct roles in the developing lung. 32:285-295. 2008
Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. 31:982-989. 2008
Effects of allergen on airway narrowing dynamics as assessed by lung-slice technique. 31:532-538. 2008
COPD dashboard: about official Documents, Authors, Science, Health status and BOARDs. 31:238-240. 2008
COPD patients' ability to follow exercise influences short-term outcomes of rehabilitation. 31:304-310. 2008
Global strategy for asthma management and prevention: GINA executive summary. 31:143-178. 2008
Population prevalence of COPD. 31:218-218. 2008
Three-dimensional computed tomography imaging in an animal model of emphysema. 30:1082-1089. 2007
"HOW MUCH IS TOO MUCH? THE TREATMENT OF MILD ASTHMA". P.M. O'BYRNE. EUR RESPIR J 2007; 30: 403 406.. 30:1026-1026. 2007
Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. 30:1014-1017. 2007
Kinetics of in vitro bronchoconstriction in an elastolytic mouse model of emphysema. 30:691-700. 2007
A common presentation with a rare cause. 30:594-597. 2007
How much is too much? The treatment of mild asthma. 30:403-406. 2007
Lung function decline in asthma. 30:411-413. 2007
Store-refilling involves both L-type calcium channels and reverse-mode sodium calcium exchange in airway smooth muscle. 30:269-278. 2007
Ionic mechanisms and Ca2+ handling in airway smooth muscle. 30:114-133. 2007
Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. 29:834-860. 2007
Regulation of airway smooth muscle RhoA/ROCK activities by cholinergic and bronchodilator stimuli. 28:703-711. 2006
Regulation of airway smooth muscle RhoA/ROCK activities by cholinergic and bronchodilator stimuli.. 28:703-711. 2006
Asthma, COPD and bronchitis are just components of airway disease. 28:264-267. 2006
Bone marrow progenitors in inflammation and repair: new vistas in respiratory biology and pathophysiology. 27:441-445. 2006
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. 27:483-494. 2006
Use of heated humidification during nasal CPAP titration in obstructive sleep apnoea syndrome. 26:679-685. 2005
Efficacy of fluticasone on cough. 26:181-181. 2005
In memoriam Romain Pauwels. 25:585-586. 2005
A randomised trial to evaluate the self-administered standardised chronic respiratory questionnaire. 25:31-40. 2005
Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. 25:41-46. 2005
Extracellular matrix regulates human airway smooth muscle cell migration. 24:545-551. 2004
Effect of freezing of sputum samples on flow cytometric analysis of lymphocyte subsets. 24:309-312. 2004
Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy?. 24:1-2. 2004
Limitation to muscular activity in chronic obstructive pulmonary disease. 24:6-7. 2004
Relationship between quality of life and clinical status in asthma: a factor analysis. 23:287-291. 2004
The influence of lung volume reduction surgery on exercise in patients with COPD. 23:269-274. 2004
A method to preserve sputum for delayed examination. 22:996-1000. 2003
Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. 22:787-794. 2003
Erratum: "Indirect airway challenges" (European Respiratory Journal (2003) vol. 21 (1050-1068)). 22:718. 2003
Murine models of asthma. 22:374-382. 2003
Indirect airway challenges. 21:1050-1068. 2003
Uptake of¹⁸fluorodeoxyglucose in the cystic fibrosis lung: a measure of lung inflammation?. 21:848-854. 2003
Clinical applications of assessment of airway inflammation using induced sputum. 20:40S-43s. 2002
The effect of postrehabilitation programmes among individuals with chronic obstructive pulmonary disease. 20:20-29. 2002
The use of induced sputum in clinical trials. 20:47S-50s. 2002
International approaches to the prescription of long-term oxygen therapy. 18:909-913. 2001
Increased detection of interleukin-;5 in sputum by addition of protease inhibitors. 18:685-691. 2001
Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma. 18:38-44. 2001
The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. 18:45-52. 2001
The reproducibility and sample size requirements of exercise-induced bronchoconstriction measurements. 17:581-588. 2001
Lipid-laden macrophages in induced sputum are a marker of oropharyngeal reflux and possible gastric aspiration. 16:1119-1122. 2000
"Induced sputum cell counts: their usefulness in clinical practice" (vol 16, pg 150, 2000). 16:1029-1029. 2000
Induced sputum cell counts: their usefulness in clinical practice. 16:150-158. 2000
Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma. 15:486-490. 2000
Comparison of two standardized methods of methacholine inhalation challenge in young adults. 15:181-184. 2000
The relationship between moisture or mould observations in houses and the state of health of their occupants. 14:1363-1367. 1999
Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. 14:1038-1043. 1999
Development and validation of a questionnaire to measure asthma control. 14:902-902. 1999
Development and validation of the Mini Asthma Quality of Life Questionnaire. 14:32-32. 1999
Measurements of dyspnoea during bronchoconstriction. 13:943-943. 1999
Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. 13:1029-1029. 1999
Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. 13:1029-1036. 1999
Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. 12:1409-1414. 1998
Evidence for mast cell activation during exercise-induced bronchoconstriction. 12:345-350. 1998
Effects of cromolyn and nedocromil on ion currents in canine tracheal smooth muscle. 12:50-56. 1998
Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators. 12:30-34. 1998
Serial sputum cell counts in the management of chronic airflow limitation. 11:1405-1408. 1998
Increases in airway eosinophils and interleukin-5 with minimal bronchoconstriction during repeated low-dose allergen challenge in atopic asthmatics. 11:821-827. 1998
Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. 11:828-834. 1998
Assessment of airway inflammation: an overview.. 26:6S-8S. 1998
Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. 11:589-593. 1998
Quality of life in patients with chronic respiratory disease: the Spanish version of the Chronic Respiratory Questionnaire (CRQ). 11:55-60. 1998
Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. European Respiratory Society. 10:2662-2689. 1997
Effects of beta-agonists on dose-response curves. 10:2434-2435. 1997
Effects of beta-agonists on dose-response curves - Reply. 10:2434-2435. 1997
Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. 10:2285-2294. 1997
Measurement characteristics of two asthma symptom diary scales for use in clinical trials. 10:646-651. 1997
Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. 10:330-336. 1997
Use of peak expiratory flow meters in adults: practical aspects.. 24:72S-74S. 1997
Comparison of reported prevalences of recent asthma in longitudinal and cross-sectional studies. 10:51-54. 1997
Induced sputum to assess airway inflammation in asthma. 9:2435-2436. 1996
A case for serial examination of sputum inflammatory cells. 9:2174-2175. 1996
Increased peak flow variability in children with asymptomatic hyperresponsiveness. 8:1731-1735. 1995
Some technical factors influencing the induction of sputum for cell analysis. 8:559-565. 1995
Immune-inflammatory functions of fibroblasts. 7:2212-2222. 1994
The effects of indomethacin on refractoriness following exercise both with and without a bronchoconstrictor response. 7:2174-2178. 1994
Granulocyte-macrophage colony-stimulating factor, eosinophils and eosinophil cationic protein in subjects with and without mild, stable, atopic asthma. 7:1576-1584. 1994
Airway inflammation in symptomatic and asymptomatic children with methacholine hyperresponsiveness. 6:1249-1256. 1993
Factors contributing to dyspnoea during bronchoconstriction and exercise in asthmatic subjects. 6:1004-1010. 1993
Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. 6:53-83. 1993
Is nedocromil sodium effective treatment for asthma?. 6:5-6. 1993
Regular beta-agonist therapy--the quality of the evidence. 5:896-897. 1992
International consensus report on diagnosis and treatment of asthma. National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication no. 92-3091, March 1992. 5:601-641. 1992
Effort and dyspnoea during work of varying intensity and duration. 4:917-925. 1991
The role of thromboxane in allergen-induced asthmatic responses. 4:667-672. 1991
Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. 4:188-190. 1991
Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. 3:1122-1127. 1990
Assessment of disability. 3:989-990. 1990
The role of thromboxane A2 in the pathogenesis of airway hyperresponsiveness. 2:782-786. 1989
Measuring health status in chronic airflow limitation. 1:560-564. 1988
Assessment of dyspnoea. 1:195-197. 1988
Asthma and the role of inflammation.. 147:16-21. 1986
Why are deaths from asthma increasing?. 147:175-181. 1986
Nasal cilia in normal man, primary ciliary dyskinesia and other respiratory diseases: analysis of motility and ultrastructure.. 127:64-70. 1983
Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance.. 121:79-88. 1982

European Respiratory Journal Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)